CD33 and acute myeloid leukemia: In immunotherapy for AML, the lack of tumor‐specific antigens can lead to targeted nontumor toxicity, the study used CRISPR–Cas9 to knockdown CD33 from healthy donor HSPC to generate the HSPC transplant product tremtelectogene empogeditemcel (trem‐cel, formerly known as VOR33, NCT04849910).